A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity

DSpace/Manakin Repository

A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity

Citable link to this page


Title: A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity
Author: Patel, Suraj J; Luther, Jay; Bohr, Stefan; Iracheta-Vellve, Arvin; Li, Matthew; King, Kevin R; Chung, Raymond T; Yarmush, Martin L

Note: Order does not necessarily reflect citation order of authors.

Citation: Patel, Suraj J, Jay Luther, Stefan Bohr, Arvin Iracheta-Vellve, Matthew Li, Kevin R King, Raymond T Chung, and Martin L Yarmush. 2016. “A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity.” Clinical and Translational Gastroenterology 7 (3): e153. doi:10.1038/ctg.2016.13. http://dx.doi.org/10.1038/ctg.2016.13.
Full Text & Related Files:
Abstract: Objectives: Acetaminophen (APAP)-induced hepatotoxicity is a major cause of morbidity and mortality. The current pharmacologic treatment for APAP hepatotoxicity, N-acetyl cysteine (NAC), targets the initial metabolite-driven injury but does not directly affect the host inflammatory response. Because of this, NAC is less effective if given at later stages in the disease course. Resolvins, a novel group of lipid mediators shown to attenuate host inflammation, may be a therapeutic intervention for APAP hepatotoxicity. Methods: The temporal patterns of liver injury and neutrophil activation were investigated in a murine model of APAP hepatotoxicity. In addition, the effect of neutrophil depletion and resolvin administration on the severity of liver injury induced by APAP was studied. In vitro studies to investigate the mechanism of resolvin effect on hepatocyte injury and neutrophil adhesion were performed. Results: We demonstrate that hepatic neutrophil activation occurs secondary to the initial liver injury induced directly by APAP. We also show that neutrophil depletion attenuates APAP-induced liver injury, and administration of resolvins hours after APAP challenge not only attenuates liver injury, but also extends the therapeutic window eightfold compared to NAC. Mechanistic in vitro analysis highlights resolvins' ability to inhibit neutrophil attachment to endothelial cells in the presence of the reactive metabolite of APAP. Conclusions: This study highlights the ability of resolvins to protect against APAP-induced liver injury and extend the therapeutic window compared to NAC. Although the mechanism for resolvin-mediated hepatoprotection is likely multifactorial, inhibition of neutrophil infiltration and activation appears to play an important role.
Published Version: doi:10.1038/ctg.2016.13
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822092/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860020
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search